Search

Your search keyword '"Bjarnason, G A"' showing total 170 results
Start Over Author "Bjarnason, G A"
170 results on '"Bjarnason, G A"'

6. Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A

Author

McDermott, D. F., Lee, J-L., Bjarnason, G. A., Larkin, J., Gafanov, R., Kochenderfer, M. D., Jensen, N. V., Donskov, F., Malik, J., Poprach, A., Tykodi, S. S., Alonso-Gordoa, T., Cho, D. C., Geertsen, P. F., Climent Duran, M. A., Di Simone, C., Liu, H., Burgents, J., Rodriguez-Lopez, K., and Atkins, M. B.

Published
2021

12. Stereotactic Radiotherapy for Oligoprogression in Metastatic Kidney Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Prospective Phase II Multi-Centre Study

Author

Cheung, P., primary, Patel, S.I., additional, North, S., additional, Sahgal, A., additional, Chu, W., additional, Soliman, H., additional, Ahmad, B., additional, Winquist, E., additional, Niazi, T.M., additional, Pantenaude, F., additional, Lim, G.W., additional, Heng, D., additional, Dubey, A., additional, Czaykowsky, P., additional, Wong, R., additional, Swaminath, A., additional, Morgan, S.C., additional, White, J., additional, Keshavarzi, S., additional, and Bjarnason, G., additional

Published
2020
Full Text
View/download PDF

14. Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting

Author

Nazha, S., primary, Tanguay, S., additional, Kapoor, A., additional, Jewett, M., additional, Kollmannsberger, C., additional, Wood, L., additional, Bjarnason, G., additional, Heng, D., additional, Soulières, D., additional, Reaume, N., additional, Basappa, N., additional, Lévesque, E., additional, and Dragomir, A., additional

Published
2018
Full Text
View/download PDF

17. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Author

Stukalin, I., Wells, J. C., Graham, J., Yuasa, T., Beuselinck, B., Kollmansberger, C., Ernst, D. S., Agarwal, N., Le, T., Donskov, F., Hansen, A. R., Bjarnason, G. A., Srinivas, S., Wood, L. A., Alva, A. S., Kanesvaran, R., Fu, S. Y. F., Davis, I. D., Choueiri, T. K., and Heng, D. Y. C.

Subjects
RENAL cell carcinoma, VASCULAR endothelial growth factor receptors
Abstract

Objectives In the present study, we explored the real-world efficacy of the immuno-oncology checkpoint inhibitor nivolumab and the tyrosine kinase inhibitor cabozantinib in the second-line setting. Methods Using the International Metastatic Renal Cell Carcinoma Database Consortium (imdc) dataset, a retrospective analysis of patients with metastatic renal cell carcinoma (mrcc) treated with nivolumab or cabozantinib in the second line after prior therapy targeted to the vascular endothelial growth factor receptor (vegfr) was performed. Baseline characteristics and imdc risk factors were collected. Overall survival (os) and time to treatment failure (ttf) were calculated using Kaplan-Meier curves. Overall response rates (orrs) were determined for each therapy. Multivariable Cox regression analysis was performed to determine survival differences between cabozantinib and nivolumab treatment. Results The analysis included 225 patients treated with nivolumab and 53 treated with cabozantinib. No significant difference in median os was observed: 22.10 months [95% confidence interval (ci): 17.18 months to not reached] with nivolumab and 23.70 months (95% ci: 15.52 months to not reached) with cabozantinib (p = 0.61). The ttf was also similar at 6.90 months (95% ci: 4.60 months to 9.20 months) with nivolumab and 7.39 months (95% ci: 5.52 months to 12.85 months) with cabozantinib (p = 0.20). The adjusted hazard ratio (hr) for nivolumab compared with cabozantinib was 1.30 (95% ci: 0.73 to 2.3), p = 0.38. When adjusted by imdc criteria and age, the hr was 1.32 (95% ci: 0.74 to 2.38), p = 0.35. Conclusions Real-world imdc data indicate comparable os and ttf for nivolumab and cabozantinib. Both agents are reasonable therapeutic options for patients progressing after initial first-line vegfr-targeted therapy. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

18. Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience

Author

Lalani, A.-K., primary, Li, H., additional, Heng, D., additional, Wood, L., additional, Kalirai, A., additional, Bjarnason, G., additional, Sim, H.-W., additional, Kollmannsberger, C.K., additional, Kapoor, A., additional, Hotte, S.J., additional, Vanhuyse, M., additional, Czaykowski, P., additional, Reaume, M.N., additional, Soulieres, D., additional, Venner, P., additional, North, S., additional, and Basappa, N., additional

Published
2016
Full Text
View/download PDF

19. Management of Kidney Cancer: Canadian Kidney Cancer Forum Consensus Update 2011: Canadian Kidney Cancer Forum 2011

Author

Jewett, MAS, Finelli, A, Kollmannsberger, C, Wood, L, Legere, L, Basiuk, J, Canil, C, Heng, D, Reaume, N, Tanguay, S, Atkins, M, Bjarnason, G, Dancey, J, Evans, M, Fleshner, N, Haider, M, Kapoor, A, Uzzo, R, Maskens, D, Soulieres, D, Yousef, G, Basappa, N, Bendali, N, Black, P, Blais, N, Cagiannos, I, Care, M, Chow, R, Chung, H, Czaykowski, P, DeRosa, D, Durrant, K, Ellard, S, Farquharson, G, Filion-Brulotte, C, Gingerich, J, Godbout, L, Grant, R, Hamilton, W, Kassouf, W, Kurban, G, Lane, K, Lattouf, JB, Lau, D, Leveridge, M, McCarthy, J, Moore, R, North, S, O’Brien, P, Pituskin, E, Racine, P, Rendon, R, So, A, Sridhar, S, Stubbs, K, Su, Z, Taylor, L, Udall, T, Venner, P, Vogel, W, Yap, S, Yau, P, Cooper, M, Giroux, N, Miron, D, Mosher, D, Ross, K, and Willacy, J

Subjects
Consensus Statement
Published
2012

20. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma

Author

Faragalla, H. Youssef, Y.M. Scorilas, A. Khalil, B. White, N.M.A. Mejia-Guerrero, S. Khella, H. Jewett, M.A.S. Evans, A. Lichner, Z. Bjarnason, G. Sugar, L. Attalah, M.I. Yousef, G.M.

Subjects
urologic and male genital diseases
Abstract

Renal cell carcinoma (RCC) is the most common neoplasm of the kidney. Increasing evidence suggests that microRNAs are dysregulated in RCC and are important factors in RCC pathogenesis. miR-21 is a known oncogene with tumor-promoting effects in many types of cancer. In this study, we analyzed miR-21 in 121 cases of healthy kidney and different RCC subtypes, including clear cell (ccRCC), papillary (pRCC), chromophobe (chRCC), and oncocytoma. Total RNA was extracted, and the expression of miR-21 was measured with real-time quantitative RT-PCR using miR-21-specific probes. The expression of miR-21 was significantly up-regulated in RCC compared with healthy kidney. There was a significant difference in the expression levels between RCC subtypes, with the highest levels of expression in ccRCC and pRCC subtypes. miR-21 expression distinguished ccRCC and pRCC from chRCC and oncocytoma with 90% specificity (95% CI, 63.9% to 98.1%) and 83% sensitivity (95% CI, 53.5% to 97.6%). Significantly higher miR-21 levels were associated with higher stage and grade. Patients who were miR-21 positive had statistically significant shorter disease-free and overall survival rates. Thus, miR-21 is up-regulated in RCC, and its expression levels can be used as a diagnostic marker to distinguish ccRCC and pRCC from chRCC and oncocytoma. Moreover, it has potential as a prognostic marker in RCC, although it is not independent of tumor stage and grade. Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Published
2012

21. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Author

Grünwald, V, Karakiewicz, P, Bavbek, S, Miller, K, Machiels, J, Lee, S, Larkin, J, Bono, P, Rha, S, Castellano, D, Blank, C, Knox, J, Hawkins, R, Anak, O, Rosamilia, M, Booth, J, Pirotta, N, Bodrogi, I, Romedi, M, Ferrandini, S, Rondinon, M, Pittman, K, Goldstein, D, Shapiro, J, Troon, S, Yip, D, Mainwaring, P, Zigeuner, R, Loidl, W, Greil, R, Schmidinger, M, De Grève, J, Rottey, S, Vermorken, J, Gil, T, Gennigens, C, Roumeguere, T, Barrios, C, Mathias, C, Assi, H, Hotte, S, Spadafora, S, Wood, L, Zalewski, P, Mackensie, M, Bjarnason, G, Lalancette, A, Chan, A, Higgins, B, North, S, Soulieres, D, Asselah, J, Sperlich, C, Miller, W, Yadav, S, El Maraghi, R, Godoy, J, Prausová, J, Katolicka, J, Petruzelka, L, Kiss, I, Lapela, M, Bergmann, L, Beck, J, Jäger, E, Kindler, M, Overkamp, F, Wirth, M, Hölzer, W, Gschwend, J, Stenzl, A, Gauler, T, Niederwieser, D, Marschner, N, Lück, A, Tessen, H, Eichelberg, C, Steiner, T, Goebell, P, Kettner, E, Bakhshandeh Bath, A, Wilhelm, M, Schmitz, S, Jacob, A, Bierer, S, Kube, U, Staehler, M, Engel, E, Frambach, M, Schellenberger, U, Albers, P, Simon, J, Gleissler, M, Klotz, T, Repp, R, Kröning, H, Westermann, J, Rebmann, U, Brehmer, B, Niederle, N, Grund, C, Verpoort, K, Fonara, P, Rassweiler, J, Bamias, A, Fountzilas, G, Razis, E, Mouratidou, D, Georgoulias, V, Samantas, E, Mangel, L, Szanto, J, Berger, R, Pe'Er, A, Sella, A, Ben Yosef, R, Nechushtan, H, Crinò, L, Bracarda, S, Ciuffreda, L, Graiff, C, Falcone, A, Roselli, M, Sternberg, C, Santoro, A, Ruggeri, E, Bearz, A, Venturini, M, Aglietta, M, Amadori, D, Di Costanzo, F, Bari, M, Gebbia, N, Conte, P, Bonetti, A, Bordonaro, R, Cascinu, S, Contu, A, Cruciani, G, Gasparro, D, Nardi, M, Lelli, G, Lo Re, G, Boccardo, F, Lorusso, V, Maiello, E, Manente, P, Passalacqua, R, Piantedosi, F, Porta, C, Sacco, C, Tondini, C, De Placido, S, Carteni, G, Dogliotto, L, Rosti, G, Milella, M, Roila, F, Amoroso, D, Farina, G, Al Khatib, H, Kim, T, Ahn, J, Lim, H, Chung, I, Kim, J, Chung, J, Ghosn, M, Shameseddine, A, Lugo, R, Cabrera, P, Osanto, S, Groenewegen, G, van den Eertwegh, F, van Herpen, C, Oosting, S, Soetekouw, P, Lilleby, W, Klepp, O, Guren, T, Alcedo, J, Karlov, P, Nosov, D, Roman, L, Rusakov, I, Bazarbashi, S, Toh, C, Mardiak, J, del Muro Solans, F, Ray, J, Mollins, J, Martinez, I, Gonzalez, B, Santasusana, M, Piqueras, M, Fuentes, J, Larriba, J, Caro, R, Garcia, A, Aparicio, L, Lopez, N, Aragon, V, Morales, C, Figueiras, M, Ibanez, J, Billalabeitia, G, Estrada, E, Arranz, J, Sorrosal, J, Lozano, A, de Villena, M, Espinosa, E, Lopez, R, Perez, J, Laurell, A, Stierner, U, Cwikiel, M, Borner, M, Dietrich, P, Rothermundt, C, Pu, Y, Chang, Y, Ou, Y, Chuang, C, Liao, Y, Srimuninnimit, V, Sriuranpong, V, Buyukberber, S, Yalcin, B, Goker, E, Yalcin, S, Geldart, T, Wagstaff, J, Nicholson, S, Chowdhury, S, Bahl, A, Jones, R, Azzabi, A, Chao, D, Fife, K, Mead, G, Nathan, P, Pandha, H, Hajdenberg, J, Gabrail, N, Nimeh, N, Logan, T, Flaig, T, Schraeder, R, Rini, B, O'Rourke, M, Alemany, C, Kessinger, A, Amin, A, Arriaga, M, Rodriguez, J, Gauler, Thomas (Beitragende*r), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and Laboratory of Molecular and Medical Oncology

Subjects
Nephrology, Oncology, Male, Cancer Research, mTOR inhibitor, Settore MED/06 - Oncologia Medica, Medizin, Advanced kidney cancer, RAD001, REACT, 0302 clinical medicine, Renal cell carcinoma, Receptors, 80 and over, Treatment Failure, Neoplasm Metastasis, Aged, 80 and over, 0303 health sciences, Vascular Endothelial Growth Factor, Sirolimus, Young Adult, Antineoplastic Agents, Humans, Aged, Immunosuppressive Agents, Protein Kinase Inhibitors, Receptors, Vascular Endothelial Growth Factor, Kidney Neoplasms, Adult, Carcinoma, Renal Cell, Middle Aged, Female, 3. Good health, 030220 oncology & carcinogenesis, Safety, medicine.drug, medicine.medical_specialty, SECOND LINE THERPAY, Second-line therapy, Everolimus, 03 medical and health sciences, Internal medicine, medicine, Adverse effect, 030304 developmental biology, business.industry, Carcinoma, Renal Cell, medicine.disease, Surgery, Clinical trial, Expanded access, business, Kidney cancer
Abstract

BACKGROUND AND OBJECTIVES: The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. The REACT (RAD001 Expanded Access Clinical Trial in RCC) study was initiated to address an unmet medical need by providing everolimus prior to commercial availability, and also to further assess the safety and efficacy of everolimus in patients with VEGFr-TKI-refractory mRCC. PATIENTS AND METHODS: REACT (Clinicaltrials.gov: NCT00655252) was a global, open-label, expanded-access programme in patients with mRCC who were intolerant of, or who had progressed on or after stopping treatment with, any available VEGFr-TKI therapy. Patients received everolimus 10mg once daily, with dose and schedule modifications allowed for toxicity. Patients were closely monitored for the development of serious and grades 3/4 adverse events (AEs). Response was assessed by RECIST every 3months for the first year and every 6months thereafter. RESULTS: A total of 1367 patients were enroled. Safety findings and tumour responses were consistent with those observed in RECORD-1, with no new safety issues identified. The most commonly reported serious AEs were dyspnoea (5.0%), pneumonia (4.7%) and anaemia (4.1%), and the most commonly reported grades 3/4 AEs were anaemia (13.4%), fatigue (6.7%) and dyspnoea (6.5%). Best overall response was stable disease in 51.6% and partial response in 1.7% of patients. Median everolimus treatment duration was 14weeks. CONCLUSION: Everolimus is well tolerated in patients with mRCC and demonstrates a favourable risk-benefit ratio.

Published
2012

22. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

Author

Gore, M E, primary, Szczylik, C, additional, Porta, C, additional, Bracarda, S, additional, Bjarnason, G A, additional, Oudard, S, additional, Lee, S-H, additional, Haanen, J, additional, Castellano, D, additional, Vrdoljak, E, additional, Schöffski, P, additional, Mainwaring, P, additional, Hawkins, R E, additional, Crinò, L, additional, Kim, T M, additional, Carteni, G, additional, Eberhardt, W E E, additional, Zhang, K, additional, Fly, K, additional, Matczak, E, additional, Lechuga, M J, additional, Hariharan, S, additional, and Bukowski, R, additional

Published
2015
Full Text
View/download PDF

23. 7 Characterizing the impact of lymph node metastases on survival outcome of metastatic renal cell carcinoma patients treated with targeted therapies

Author

Kröger, N., primary, Pantuck, A., additional, Wells, C., additional, Lawrence, N., additional, Broom, R., additional, Kim, J., additional, Srinivas, S., additional, Yim, J., additional, Bjarnason, G., additional, Templeton, A., additional, Knox, J., additional, Bernstein, E., additional, Smoragiewicz, M., additional, Lee, J., additional, Rini, B., additional, Vaishampayan, U., additional, Beuselinck, B., additional, Donskov, F., additional, Choueiri, T., additional, and Heng, D., additional

Published
2015
Full Text
View/download PDF

24. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

Author

Jonker, DJ, Karapetis, CS, Harbison, C, O'Callaghan, CJ, Tu, D, Simes, RJ, Malone, DP, Langer, C, Tebbutt, N, Price, TJ, Shapiro, J, Siu, LL, Wong, RPW, Bjarnason, G, Moore, MJ, Zalcberg, JR, Khambata-Ford, S, Jonker, DJ, Karapetis, CS, Harbison, C, O'Callaghan, CJ, Tu, D, Simes, RJ, Malone, DP, Langer, C, Tebbutt, N, Price, TJ, Shapiro, J, Siu, LL, Wong, RPW, Bjarnason, G, Moore, MJ, Zalcberg, JR, and Khambata-Ford, S

Abstract

BACKGROUND: Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy-refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit. METHODS: Tumour samples from a phase III clinical trial of cetuximab plus best supportive care (BSC) vs BSC alone (CO.17) were analysed for EREG mRNA gene expression. Predictive effects of high vs low EREG on OS and progression-free survival (PFS) were examined for treatment-biomarker interaction. RESULTS: Both EREG and K-ras status were ascertained in 385 (193 cetuximab, 192 BSC) tumour samples. Within the high EREG and K-ras wild-type status ('co-biomarker')-positive group (n=139, 36%), median PFS was 5.4 vs 1.9 months (hazard ratio (HR) 0.31; P<0.0001), and median OS was 9.8 vs 5.1 months (HR 0.43; P<0.001) for cetuximab vs BSC, respectively. In the rest (n=246, 64%), PFS (HR 0.82; P=0.12) and OS (HR 0.90; P=0.45) were not significantly different. Test for treatment interaction showed a larger cetuximab effect on OS (HR 0.52; P=0.007) and PFS (HR 0.49; P=0.001) in the co-biomarker-positive group. CONCLUSION: In pre-treated K-ras wild-type status colorectal cancer, patients with high EREG gene expression appear to benefit more from cetuximab therapy compared with low expression. Epiregulin as a selective biomarker requires further evaluation.

Published
2014

26. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

Author

Ko, J J, primary, Choueiri, T K, additional, Rini, B I, additional, Lee, J-L, additional, Kroeger, N, additional, Srinivas, S, additional, Harshman, L C, additional, Knox, J J, additional, Bjarnason, G A, additional, MacKenzie, M J, additional, Wood, L, additional, Vaishampayan, U N, additional, Agarwal, N, additional, Pal, S K, additional, Tan, M-H, additional, Rha, S Y, additional, Yuasa, T, additional, Donskov, F, additional, Bamias, A, additional, and Heng, D Y C, additional

Published
2014
Full Text
View/download PDF

28. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

Author

Jonker, D J, primary, Karapetis, C S, additional, Harbison, C, additional, O'Callaghan, C J, additional, Tu, D, additional, Simes, R J, additional, Malone, D P, additional, Langer, C, additional, Tebbutt, N, additional, Price, T J, additional, Shapiro, J, additional, Siu, L L, additional, Wong, R P W, additional, Bjarnason, G, additional, Moore, M J, additional, Zalcberg, J R, additional, and Khambata-Ford, S, additional

Published
2013
Full Text
View/download PDF

30. Water Influence on Bearing Capacity and Pavement Performance : Field Observations

Author

Charlier, R, Hornych, P, Srsen, M, Hermansson, A, Bjarnason, G, Erlingsson, Sigurd, Pavsic, P, Charlier, R, Hornych, P, Srsen, M, Hermansson, A, Bjarnason, G, Erlingsson, Sigurd, and Pavsic, P

Abstract

This chapter presents a mechanical behaviour study, i.e. the bearing capacity as a function of the moisture degree. The field point of view is expressed and the chapter summarises a number of observations on road behaviour, in relation to variations of moisture. First, the road structure is recalled with respect to the mechanical analysis point of view. Then some observations on field under temperate climate, humid, are given. In a second step, the specific case of frost and thawing are discussed., TSC import 1859 2012-02-14. QC 20120427

Published
2009
Full Text
View/download PDF

34. Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963.

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Levi, F, Humblet, Yves, Gorlia, Thierry, Tubiana, N, Smaaland, R, Canon, JL., Lentz, MA., Focan, C., Bjarnason, G, Giacchetti, S, 41st Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Levi, F, Humblet, Yves, Gorlia, Thierry, Tubiana, N, Smaaland, R, Canon, JL., Lentz, MA., Focan, C., Bjarnason, G, Giacchetti, S, and 41st Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2005

38. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.

Author

Fuchs, C. S., primary, Tepper, J. E., additional, Niedzwiecki, D., additional, Hollis, D., additional, Mamon, H. J., additional, Swanson, R., additional, Haller, D. G., additional, Dragovich, T., additional, Alberts, S. R., additional, Bjarnason, G. A., additional, Willett, C. G., additional, Enzinger, P. C., additional, Goldberg, R. M., additional, Venook, A. P., additional, and Mayer, R. J., additional

Published
2011
Full Text
View/download PDF

39. Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC).

Author

Bjarnason, G. A., primary, Williams, R., additional, Hudson, J. M., additional, Bailey, C., additional, Lee, C. R., additional, Lloyd, B. A., additional, Kandel, S., additional, Ebos, J. M., additional, Kiss, A., additional, Kerbel, R. S., additional, Milot, L. M., additional, Atri, M., additional, Stanisz, G. J., additional, and Burns, P., additional

Published
2011
Full Text
View/download PDF

42. It is time for chronotherapy!

Author

UCL, Coudert, B., Bjarnason, G, Focan, C., di Paola, ED, Levi, F, UCL, Coudert, B., Bjarnason, G, Focan, C., di Paola, ED, and Levi, F

Abstract

The EORTC Chronotherapy Group (CTG) stemmed from the International Organisation for Cancer Chronotherapy(IOCC) in 1996. The IOCC was the first to initiate large scale multicentre international chronotherapy trials, for the purpose of investigating the relevance of chronomodulated or timed administration of cancer therapy based on biological rhythms. Programmable pumps for cytotoxic chronodelivery and actigraph devices to monitor circadian rhythm alterations linked to cancer were also developed. The unique expertise of the IOCC with regard to cancer chronotherapy furthered its development within the EORTC. EORTC offers broad expertise in clinical cancer research and opportunities for scientific recognition, inter-group collaborations and translational research. Over the past 5 years, EORTC CTG has grown from 16 to 48 centres in 12 different countries. It is currently conducting seven multicentre chronotherapy trials, which test the relevance of adapting cancer treatment delivery to circadian rhythms. The group aims at developing multiple collaborations to establish a chronotherapy network involving institutions with expertise ranging from experimental chronobiology to new drug testing, disease-specific management and quality of life or survival issues. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

Published
2003

43. A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study.

Author

Heng, D. Y., primary, Xie, W., additional, Bjarnason, G. A., additional, Vaishampayan, U. N., additional, Donskov, F., additional, Wood, L., additional, Knox, J. J., additional, Tan, M., additional, Kollmannsberger, C. K., additional, Rini, B. I., additional, and Choueiri, T. K., additional

Published
2010
Full Text
View/download PDF

45. 18-months of UV irradiance observations from the Solar Mesosphere Explorer

Author

London, J, Bjarnason, G. G, and Rottman, G. J

Subjects
Geophysics
Abstract

An instrument on the Solar Mesosphere Explorer has been making daily solar irradiance measurements in the 120-305 nm (UV) spectral interval since October 6, 1981. Calculations of the highest to lowest value of the irradiance within each solar rotation yield percent range values indicative of variations that are useful as input data for model calculations of stratosphere/mesosphere responses to short period solar variability, since solar radiation in the UV is largely responsible for the photochemical interactions and radiative heating of the stratosphere, mesosphere, and lower thermosphere.

Published
1984

Catalog

Books, media, physical & digital resources
See catalog results